

Supplementary Table S1. Characteristics of registry data included in the study.

Name of Registry	Time period	Number of prospective cases with known outcome	Number of ongoing pregnancies or lost to follow up	Comment
French Regional Centers of Pharmacovigilance (FRCP)	1990 through August 2009 (17/31 centers)	31	Not reported	Cases exposed to adalimumab (3), etanercept (13) or infliximab (15)
The Norwegian Medicines Agency (NOMA)	2002 through May 2014	17 ¹	5	Cases exposed to adalimumab (8), etanercept (2) or infliximab (7)
GlaxoSmithKline (GSK)	Cumulative through March 2015	153 ²	74	Cases exposed to belimumab
Janssen Pharmaceutical Companies of Johnson & Johnson	Cumulative through December 2012	81	85	Cases exposed to ustekinumab
Roche	December 2009 through December 2014	449 ³	712	Cases exposed to mycophenolate mofetil (202), rituximab (67) or tocilizumab (180)
Swedish Orphan Biovitrum (Sobi)	Cumulative through December 2014	26	22	Cases exposed to anakinra

¹ Spontaneous reports, not stated whether prospective or retrospective

² 1 retrospective case

³ 48 retrospective cases with exposure to rituximab